Galmed Pharmaceuticals (NASDAQ:GLMD) Posts Quarterly Earnings Results, Beats Expectations By $1.43 EPS

Galmed Pharmaceuticals (NASDAQ:GLMD) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $1.43, FiscalAI reports.

Galmed Pharmaceuticals Trading Up 8.2%

NASDAQ:GLMD opened at $0.53 on Thursday. The stock’s 50-day moving average is $0.63 and its 200-day moving average is $0.96. Galmed Pharmaceuticals has a 1-year low of $0.41 and a 1-year high of $2.68. The stock has a market cap of $2.90 million, a P/E ratio of -1.66 and a beta of 0.47.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned about 1.28% of Galmed Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 76.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.